Showing 15 posts of 69 posts found.


Prostate Cancer ‘super responders’ could live for two more years on Keytruda

November 28, 2019
Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer

Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …


Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma

November 25, 2019
Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …


Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma

October 21, 2019
Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …


BMS unveils strong five-year efficacy data for Opdivo in lung cancer

September 11, 2019
Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma

Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …


Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies

August 29, 2019
Research and Development Cancer, Celgene, immatics, immunotherapy, pharma

Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion …


Scientists use duoCAR-T therapy to fight HIV

August 9, 2019
Medical Communications AIDS, CAR-T therapy, HIV, health, immunotherapy, pharma

Researchers from the University of Pittsburgh, working with the biotech Lentigen, have found that an advanced form of CAR-T therapy …

Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial

August 5, 2019
Sales and Marketing Cancer, Roche, bladder cancer, immunotherapy, oncology, tecentriq

Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of …


Pfizer immune-oncology leader joins Aduro Biotech as new CMO

April 23, 2019
Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology

Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, …

Bowel cancers adjust themselves to hide from immunotherapies

April 15, 2019
Sales and Marketing CEA, Cancer, bowel cancer, immunotherapy, oncology, tumour

Bowel cancers can avoid being caught by immunotherapy by ‘switching off’ a molecule on the surface of cells that is …


GSK buys Merck KGaA’s cancer immunotherapy for $4.2 billion

February 6, 2019
Research and Development GSK, M7824, Merck, immunotherapy

British multinational GlaxoSmithKline has agreed to pay up to €3.7 billion ($4.2 billion) for the rights to Merck KGaA’s next …

Tumours with large number of mutations respond better to immunotherapies, study shows

January 15, 2019
Manufacturing and Production, Research and Development Cancer, immunotherapy, nature, oncology, research, tumour

Tumours with a large number of DNA mutations are more likely to respond to immunotherapies than cancers with fewer mutations, …


Nobel Prize awarded to immuno-oncology innovators

October 2, 2018
Manufacturing and Production Cancer, Nobel Prize, immunotherapy, kyoto, oncology, texas

The Nobel Prize for physiology or medicine has been awarded to both Professor James P Allison and Tasuku Honjo for …


Antibody therapy supresses HIV for months after treatment, study shows

October 1, 2018
Sales and Marketing HIV, immunology, immunotherapy, nature, research

Researchers from the New York City based Rockefeller University have developed a novel immunotherapy, which is capable of suppressing HIV …

Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3

May 29, 2018
Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …


Lilly hires new leader of immuno-oncology

May 1, 2018
Manufacturing and Production, Medical Communications Eli Lilly, biotech, drugs, immunoconlogy, immunotherapy, pharma, pharmaceutical

Immuno-oncology has become a huge area of the oncology market, led by the wave of PD-1/L1 drugs that are reaping …

Latest content